These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36035424)

  • 1. Delayed payment schemes in Central-Eastern Europe and Middle-East.
    Ádám I; Callenbach M; Németh B; Vreman RA; Pontén J; Strbad T; Dawoud D; Kostyuk A; Seyam A; Nagy L; Goettsch WG; Kaló Z
    Front Med (Lausanne); 2022; 9():940371. PubMed ID: 36035424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome-based reimbursement in Central-Eastern Europe and Middle-East.
    Ádám I; Callenbach M; Németh B; Vreman RA; Tollin C; Pontén J; Dawoud D; Elvidge J; Crabb N; van Waalwijk van Doorn-Khosrovani SB; Pisters-van Roy A; Vincziczki Á; Almomani E; Vajagic M; Oner ZG; Matni M; Fürst J; Kahveci R; Goettsch WG; Kaló Z
    Front Med (Lausanne); 2022; 9():940886. PubMed ID: 36213666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reimbursement and payment models in Central and Eastern European as well as Middle Eastern countries: A survey of their current use and future outlook.
    Callenbach MHE; Ádám L; Vreman RA; Németh B; Kaló Z; Goettsch WG
    Drug Discov Today; 2023 Jan; 28(1):103433. PubMed ID: 36372328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries.
    Kovács S; Kaló Z; Daubner-Bendes R; Kolasa K; Hren R; Tesar T; Reckers-Droog V; Brouwer W; Federici C; Drummond M; Zemplényi AT
    Health Econ; 2022 Sep; 31 Suppl 1(Suppl 1):195-206. PubMed ID: 35322478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countries.
    Kaló Z; Niewada M; Bereczky T; Goettsch W; Vreman RA; Xoxi E; Trusheim M; Callenbach MHE; Nagy L; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):181-187. PubMed ID: 37970637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges.
    Daubner-Bendes R; Kovács S; Niewada M; Huic M; Drummond M; Ciani O; Blankart CR; Mandrik O; Torbica A; Yfantopoulos J; Petrova G; Holownia-Voloskova M; Taylor RS; Al M; Piniazhko O; Lorenzovici L; Tarricone R; Zemplényi A; Kaló Z
    Front Public Health; 2020; 8():612410. PubMed ID: 33490024
    [No Abstract]   [Full Text] [Related]  

  • 7. Recommendations for patient involvement in health technology assessment in Central and Eastern European countries.
    Jakab I; Dimitrova M; Houÿez F; Bereczky T; Fövényes M; Maravic Z; Belina I; Andriciuc C; Tóth K; Piniazhko O; Hren R; Gutierrez-Ibarluzea I; Czech M; Tesar T; Niewada M; Lorenzovici L; Kamusheva M; Manova M; Savova A; Mitkova Z; Tachkov K; Németh B; Petykó ZI; Dawoud D; Delnoij D; Knies S; Goettsch W; Kaló Z
    Front Public Health; 2023; 11():1176200. PubMed ID: 37465169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies.
    Michelsen S; Nachi S; Van Dyck W; Simoens S; Huys I
    Front Pharmacol; 2020; 11():594446. PubMed ID: 33363468
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review.
    Kawalec P; Tesar T; Vostalova L; Draganic P; Manova M; Savova A; Petrova G; Rugaja Z; Männik A; Sowada C; Stawowczyk E; Harsanyi A; Inotai A; Turcu-Stiolica A; Gulbinovič J; Pilc A
    Front Pharmacol; 2017; 8():892. PubMed ID: 29326583
    [No Abstract]   [Full Text] [Related]  

  • 10. When Reality Does Not Meet Expectations-Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs.
    Callenbach MHE; Vreman RA; Mantel-Teeuwisse AK; Goettsch WG
    Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel.
    Facey KM; Espin J; Kent E; Link A; Nicod E; O'Leary A; Xoxi E; van de Vijver I; Zaremba A; Benisheva T; Vagoras A; Upadhyaya S
    Pharmacoeconomics; 2021 Sep; 39(9):1021-1044. PubMed ID: 34231135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping Payment and Pricing Schemes for Health Innovation: Protocol of a Scoping Literature Review.
    Ardito V; Cavallaro L; Drummond M; Ciani O
    Pharmacoecon Open; 2024 May; ():. PubMed ID: 38773050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring payment schemes used to promote integrated chronic care in Europe.
    Tsiachristas A; Dikkers C; Boland MR; Rutten-van Mölken MP
    Health Policy; 2013 Dec; 113(3):296-304. PubMed ID: 23937868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging lessons from regional and state innovation in value-based payment reform: balancing collaboration and disruptive innovation.
    Conrad DA; Grembowski D; Hernandez SE; Lau B; Marcus-Smith M
    Milbank Q; 2014 Sep; 92(3):568-623. PubMed ID: 25199900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.
    Vreman RA; Broekhoff TF; Leufkens HG; Mantel-Teeuwisse AK; Goettsch WG
    Int J Environ Res Public Health; 2020 Nov; 17(22):. PubMed ID: 33182732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Illustrating the Financial Consequences of Outcome-Based Payment Models From a Payers Perspective: The Case of Autologous Gene Therapy Atidarsagene Autotemcel (Libmeldy®).
    Callenbach MHE; Schoenmakers D; Vreman RA; Vijgen S; Timmers L; Hollak CEM; Mantel-Teeuwisse AK; Goettsch WG
    Value Health; 2024 May; ():. PubMed ID: 38795960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value-based payment for high-cost treatments in Singapore: a qualitative study of stakeholders' perspectives.
    Bayani DB; Wee HL
    Int J Technol Assess Health Care; 2024 Apr; 40(1):e22. PubMed ID: 38629196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pricing and reimbursement frameworks in Central Eastern Europe: a decision tool to support choices.
    Kolasa K; Kalo Z; Hornby E
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):145-55. PubMed ID: 24964864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
    Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
    Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.